Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pertuzumab - Genentech/Roche

Drug Profile

Pertuzumab - Genentech/Roche

Alternative Names: Anti-2C4 monoclonal antibody; Omnitarg; Perjeta; R-1273; RG-1273; rhuMab-2C4; rhuMAb2C4; Ro 436-8451/F01; RO-4368451-F01; RO4368451

Latest Information Update: 12 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech; Roche
  • Developer Chugai Pharmaceutical; Dana-Farber Cancer Institute; FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO; Genentech; International Breast Cancer Study Group; Japan Breast Cancer Research Group; Medica Scientia Innovation Research; Roche; West German Study Group
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Dimerisation inhibitors; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase III Ovarian cancer
  • Phase II Brain metastases; Colorectal cancer
  • Discontinued Gastric cancer; Non-small cell lung cancer; Prostate cancer

Most Recent Events

  • 07 Aug 2019 Memorial Sloan Kettering Cancer Center and Genentech completes a phase II trial for Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, second-line therapy or greater) in USA (NCT01276041)
  • 28 Jul 2019 No recent reports of development identified for phase-I development in Breast-cancer(Combination therapy, Early-stage disease, Monotherapy, Second-line therapy or greater) in New Zealand (SC, Injection)
  • 31 May 2019 Safety and efficacy data from the phase III PUFFIN trial in Breast cancer presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top